I wouldn't call it risk-less.
It's currently in preclinical demonstrating synergy and heart protection. Can we say without a doubt that this combination of drugs will work? If this was the case, we wouldn't be at $3... we would be significantly higher.
And the process still needs to be done the same way ie clinical trials and paying for those clinical trials and all the work that goes with it. I don't think you can skip P2/P3 trials just because you're creating a new drug formulation that has both drugs. Remembering also that marketing and P4(post marketing) will also add additional costs.
Are the companies making a lot of money from this? Yes, but do all companies make the same amount of money from all drugs? Not necessarily.
Ann: Expanded Heart Protection Discovery for Zantrene, page-162
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |